Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
NGM Biopharmaceuticals, Inc is a biotechnology business based in the US. NGM Biopharmaceuticals shares (NGM) are listed on the NASDAQ and all prices are listed in US Dollars. NGM Biopharmaceuticals employs 186 staff and has a trailing 12-month revenue of around USD$98.7 million.
Since the stock market crash in March caused by coronavirus, NGM Biopharmaceuticals's share price has had significant positive movement.
Its last market close was USD$20.63, which is 21.52% up on its pre-crash value of USD$16.19 and 123.15% up on the lowest point reached during the March crash when the shares fell as low as USD$9.245.
If you had bought USD$1,000 worth of NGM Biopharmaceuticals shares at the start of February 2020, those shares would have been worth USD$693.37 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$1,214.28.
|Latest market close||USD$20.63|
|52-week range||USD$9.245 - USD$24.54|
|50-day moving average||USD$18.8536|
|200-day moving average||USD$19.1158|
|Wall St. target price||USD$30.56|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.457|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-20)||-11.80%|
|1 month (2020-10-30)||18.97%|
|3 months (2020-08-28)||14.23%|
|6 months (2020-05-28)||1.13%|
|1 year (2019-11-27)||26.02%|
|2 years (2018-11-26)||N/A|
|3 years (2017-11-26)||N/A|
|5 years (2015-11-26)||N/A|
|Revenue TTM||USD$98.7 million|
|Gross profit TTM||USD$41.3 million|
|Return on assets TTM||-16.3%|
|Return on equity TTM||-29.37%|
|Market capitalisation||USD$1.6 billion|
TTM: trailing 12 months
There are currently 4.0 million NGM Biopharmaceuticals shares held short by investors – that's known as NGM Biopharmaceuticals's "short interest". This figure is 1.5% down from 4.0 million last month.
There are a few different ways that this level of interest in shorting NGM Biopharmaceuticals shares can be evaluated.
NGM Biopharmaceuticals's "short interest ratio" (SIR) is the quantity of NGM Biopharmaceuticals shares currently shorted divided by the average quantity of NGM Biopharmaceuticals shares traded daily (recently around 135114.98305085). NGM Biopharmaceuticals's SIR currently stands at 29.5. In other words for every 100,000 NGM Biopharmaceuticals shares traded daily on the market, roughly 29500 shares are currently held short.
However NGM Biopharmaceuticals's short interest can also be evaluated against the total number of NGM Biopharmaceuticals shares, or, against the total number of tradable NGM Biopharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case NGM Biopharmaceuticals's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 NGM Biopharmaceuticals shares in existence, roughly 60 shares are currently held short) or 0.1592% of the tradable shares (for every 100,000 tradable NGM Biopharmaceuticals shares, roughly 159 shares are currently held short).
A SIR above 20% would generally be considered very high, pointing to a pessimistic outlook for the share price, with a discouraging number of investors currently willing to bet against NGM Biopharmaceuticals.
Find out more about how you can short NGM Biopharmaceuticals stock.
We're not expecting NGM Biopharmaceuticals to pay a dividend over the next 12 months.
NGM Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of novel therapeutics for the treatment of cardio-metabolic, liver, oncologic, and ophthalmic diseases. The company's product candidates include Aldafermin, an engineered variant of the FGF19 human hormone in Phase 2b clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); NGM313, an agonistic antibody that activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase 1b clinical trial for use in the treatment of type 2 diabetes and NASH; and NGM395, which is engineered variant of the GDF15 human hormone for use in the treatment of metabolic syndrome. Its products under development also comprise NGM120, an inhibitory antibody binding glial cell-derived neurotrophic factor receptor alpha-like that is in Phase 1 clinical trials to inhibit the effects of elevated GDF15 levels on cancer anorexia/cachexia syndrome; NGM217, an antibody in Phase 1 clinical trials to restore pancreatic islet function and increase insulin production in patients with diabetes; and NGM621, an antibody in Phase 1 clinical trials to decrease levels of a protein implicated in the dry form of AMD. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California.
Steps to owning and managing CCF, with 24-hour and historical pricing before you buy.
Steps to owning and managing CDW, with 24-hour and historical pricing before you buy.
Steps to owning and managing CWH, with 24-hour and historical pricing before you buy.
Steps to owning and managing CBIO, with 24-hour and historical pricing before you buy.
Steps to owning and managing BLIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing CVGW, with 24-hour and historical pricing before you buy.
Steps to owning and managing AEGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing AJG, with 24-hour and historical pricing before you buy.
Steps to owning and managing ABB, with 24-hour and historical pricing before you buy.
Steps to owning and managing YGYI, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.